目的：评估非散光型后房型人工晶状体矫正高度近视伴中度散光的有效性及安全性。

方法：回顾性分析2013-12/2015-12于我院行非散光型后房型人工晶状体(V4c-ICL)植入术矫正高度近视伴中度散光(-1.00～-2.00D)的患者31例44眼，随访14.52±2.40mo，观察手术前后视力、眼压、前房深度、角膜内皮细胞计数及术后拱高、并发症、患者满意度等情况。

结果：末次随访时，本组患者有效指数为1.38±0.35，安全指数为1.42±0.30，裸眼视力和矫正视力(LogMAR)均优于术前(0.05±0.15 vs 1.48±0.29； 0.03±0.12 vs 0.18±0.15； 均P<0.05)，前房深度低于术前(2.22±0.28mm vs 3.19±0.20mm，P<0.05)，而眼压和角膜内皮细胞计数均与术前无差异(P>0.05)。至末次随访，本组患者均未发生严重的眼部并发症，总满意度为94%。

结论：非散光型后房型人工晶状体矫正高度近视伴中度散光安全有效。

METHODS: This retrospective study included 31 patients(44 eyes)with high myopia and moderate astigmatism who had posterior chamber intraocular lens(V4c)implantation surgery in our hospital from December 2013 to December 2015(astigmatism in the range of -1.00 to -2.00D). The last follow-up time was 14.52±2.40mo. Visual acuity, intraocular pressure, anterior chamber depth, corneal endothelial cell density, vault, complications, patient satisfaction, etc. were observed pre- and postoperative.

RESULTS: At the last follow-up, the effective index of this group was 1.38±0.35, the safety index was 1.42±0.30. The uncorrected visual acuity and corrected visual acuity(LogMAR)was better than preoperative(0.05±0.15 vs 1.48±0.29; 0.03±0.12 vs 0.18± 0.15; all P<0.05), the anterior chamber depth was lighter than preoperative(2.22±0.28mm vs 3.19±0.20mm, P<0.05), and there was no difference between intraocular pressure and corneal endothelial cell density(P>0.05). At the last follow-up, no serious eye complications occurred in this group, and the total satisfaction was 94%.

CONCLUSION: Non-astigmatic posterior chamber implantable intraocular lens is a safe and effective solution for high myopia with moderate astigmatism.